...
首页> 外文期刊>Expert opinion on biological therapy >Mesenchymal stem cell therapy for chronic renal failure.
【24h】

Mesenchymal stem cell therapy for chronic renal failure.

机译:间充质干细胞治疗慢性肾功能衰竭。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

IMPORTANCE OF THE FIELD: Chronic kidney disease (CKD) has become a worldwide public health problem. Renal transplantation is the treatment of choice for end-stage renal disease, but is limited by a small number of organ donors and the immune barrier. To overcome these problems, new therapeutic strategies for tissue repair have recently emerged. AREAS COVERED IN THIS REVIEW: We discuss the therapeutic potential of mesenchymal stem cells (MSCs) in kidney injury and examine the latest reports providing evidence supporting MSC efficacy in the treatment of chronic renal failure (CRF). WHAT THE READER WILL GAIN: MSCs improve histological and functional outcomes in various CRF model systems. Paracrine effects rather than transdifferentiation might result in the prevention of progressive renal failure. In addition, MSCs can reprogram kidney cell differentiation, and modulate neo-kidney transplantation in CRF. TAKE HOME MESSAGE: Although many practical problems remain to be addressed, treatment with MSCs will enter the mainstream of CRF treatment.
机译:领域的重要性:慢性肾脏病(CKD)已成为全球性的公共卫生问题。肾移植是终末期肾脏疾病的首选治疗方法,但受少数器官供体和免疫屏障的限制。为了克服这些问题,最近出现了用于组织修复的新治疗策略。本综述涵盖的领域:我们讨论了间充质干细胞(MSCs)在肾脏损伤中的治疗潜力,并研究了最新报道,这些证据提供了支持MSC在治疗慢性肾功能衰竭(CRF)中的证据。读者的收获:MSC可改善各种CRF模型系统中的组织学和功能结果。旁分泌作用而不是转分化作用可能导致预防进行性肾衰竭。此外,MSC可以重新编程肾细胞分化,并调节CRF中的新肾移植。寄语:尽管仍有许多实际问题需要解决,但用MSC进行治疗将成为CRF治疗的主流。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号